OPHIREX, INC
Federal contract awards won by OPHIREX, INC (UEI W452WY5E2JQ9), 2020–2023 — public record from USAspending.
Showing awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
4
awards
0
expiring in 12 months
1
agency
Agencies buying from OPHIREX, INC
What OPHIREX, INC has provided
Awards
DHA PH II SEQL PROPOSAL H2S-0045, TITLE: BROAD-SPECTRUM SNAKEBITE ANTIDOTE: METALLOPROTEASE INHIBITION TO IMPROVE RECOVERY TIME FOLLOWING SNAKEBITE, MEDICAL R & D EGS 23000510
Department of Defense · $1,299,779 · Aug 25, 2023
FOLLOW ON PHASE III RESEARCH AND DEVELOPMENT SBIR FOR PROJECT TITLED, BROAD-SPECTRUM SNAKEBITE ANTIDOTE: ORAL PRODUCT DEVELOPMENT AND IV CLINICAL STUDY
Department of Defense · $13,827,499 · Apr 5, 2022
COVID-19 DHA 2018.1 SBIR PHASE III MEDICAL R&D CONTRACT PROPOSAL TITLED: "TARGETING SPLA2 FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ASSOCIATED WITH SARS-COV-2" LOG #19000053
Department of Defense · $10,571,594 · Jun 19, 2020
ARMY MEDICAL RESEARCH AND DEVELOPMENT SBIR PHASE III CONTRACT TITLED ADVANCEMENT OF ADVANCEMENT BROAD-SPECTRUM SNAKEBITE ANTIDOTE.
Department of Defense · $9,407,618 · Jun 1, 2020